Michael Black

Prof. Michael Black

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2004 in Nature
Verified
Journal Article
Closed access
PDF file
ZLZachary Lippman
Zachary Lippman
AGAnne-Valerie Gendrel
Anne-Valerie Gendrel
MBMichael Black
Michael Black
MVMatthew W. Vaughn
Matthew W. Vaughn
NDNeilay Dedhia
Neilay Dedhia
RMRob Martienssen
Rob Martienssen

7 April 2011 in BMJ
Verified
Journal Article
Open access
PDF file
RNR. A. North
R. A. North
LML. M. E. McCowan
L. M. E. McCowan
GDG. A. Dekker
G. A. Dekker
LPLucilla Poston
Lucilla Poston
ECEliza H Y Chan
Eliza H Y Chan
LKLouise C Kenny
Louise C Kenny
Objectives To develop a predictive model for pre-eclampsia based on clinical risk factors for nulliparous women and to identify a subgroup at increased risk, in whom specialist referral might be indicated. Design Prospective multicentre cohort. Setting Five centres in Auckland, New Zealand; Adelaide, Australia; Manchester and London, United Kingdom; and Cork, Republic of Ireland. Participants 3572 “healthy” nulliparous women with a singleton pregnancy from a large international study; data on pregnancy outcome were available for 3529 (99%). Main outcome measure Pre-eclampsia defined as ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, or both, on at least two occasions four hours apart after 20 weeks’ gestation but before the onset of labour, or postpartum, with either proteinuria or any multisystem complication. Preterm pre-eclampsia was defined as women with pre-eclampsia delivered before 37+0 weeks’ gestation. In the stepwise logistic regression the comparison group was women without pre-eclampsia. Results Of the 3529 women, 186 (5.3%) developed pre-eclampsia, including 47 (1.3%) with preterm pre-eclampsia. Clinical risk factors at 14-16 weeks’ gestation were age, mean arterial blood pressure, body mass index (BMI), family history of pre-eclampsia, family history of coronary heart disease, maternal birth weight, and vaginal bleeding for at least five days. Factors associated with reduced risk were a previous single miscarriage with the same partner, taking at least 12 months to conceive, high intake of fruit, cigarette smoking, and alcohol use in the first trimester. The area under the receiver operating characteristics curve (AUC), under internal validation, was 0.71. Addition of uterine artery Doppler indices did not improve performance (internal validation AUC 0.71). A framework for specialist referral was developed based on a probability of pre-eclampsia generated by the model of at least 15% or an abnormal uterine artery Doppler waveform in a subset of women with single risk factors. Nine per cent of nulliparous women would be referred for a specialist opinion, of whom 21% would develop pre-eclampsia. The relative risk for developing pre-eclampsia and preterm pre-eclampsia in women referred to a specialist compared with standard care was 5.5 and 12.2, respectively. Conclusions The ability to predict pre-eclampsia in healthy nulliparous women using clinical phenotype is modest and requires external validation in other populations. If validated, it could provide a personalised clinical risk profile for nulliparous women to which biomarkers could be added. Trial registration ACTRN12607000551493.

22 September 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SCSilvia Cappello
Silvia Cappello
MGMary J Gray
Mary J Gray
CBCaroline Badouel
Caroline Badouel
SLSimona Lange
Simona Lange
MEMelanie Einsiedler
Melanie Einsiedler
SRStephen Robertson
Stephen Robertson

1 March 2016 in Molecular Ecology
Verified
Journal Article
Closed access
PDF file
ETErica V. Todd
Erica V. Todd
MBMichael Black
Michael Black
NGNeil Gemmell
Neil Gemmell

30 July 2018 in OncoImmunology
Verified
Journal Article
Open access
ATAlexandra Thomas
Alexandra Thomas
EREric D. Routh
Eric D. Routh
APAshok Pullikuth
Ashok Pullikuth
GJGuangxu Jin
Guangxu Jin
JSJing Su
Jing Su
LMLance Miller
Lance Miller
Mounting evidence supports a role for the immune system in breast cancer outcomes. The ability to distinguish highly immunogenic tumors susceptible to anti-tumor immunity from weakly immunogenic or inherently immune-resistant tumors would guide development of therapeutic strategies in breast cancer. Genomic, transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) breast cancer cohorts were used to examine statistical associations between tumor mutational burden (TMB) and the survival of patients whose tumors were assigned to previously-described prognostic immune subclasses reflecting favorable, weak or poor immune-infiltrate dispositions (FID, WID or PID, respectively). Tumor immune subclasses were associated with survival in patients with high TMB (TMB-Hi, P < 0.001) but not in those with low TMB (TMB-Lo, P = 0.44). This statistical relationship was confirmed in the METABRIC cohort (TMB-Hi, P = 0.047; TMB-Lo, P = 0.39), and also found to hold true in the more-indolent Luminal A tumor subtype (TMB-Hi, P = 0.011; TMB-Lo, P = 0.91). In TMB-Hi tumors, the FID subclass was associated with prolonged survival independent of tumor stage, molecular subtype, age and treatment. Copy number analysis revealed the reproducible, preferential amplification of chromosome 1q immune-regulatory genes in the PID immune subclass. These findings demonstrate a previously unappreciated role for TMB as a determinant of immune-mediated survival of breast cancer patients and identify candidate immune-regulatory mechanisms associated with immunologically cold tumors. Immune subtyping of breast cancers may offer opportunities for therapeutic stratification.

15 March 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KMKaren M. Mann
Karen M. Mann
JWJerrold M. Ward
Jerrold M. Ward
CYChristopher Chin Kuan Yew
Christopher Chin Kuan Yew
AKAnne Kovochich
Anne Kovochich
DDDavid W. Dawson
David W. Dawson
NCNeal G. Copeland
Neal G. Copeland
Pancreatic cancer is one of the most deadly cancers affecting the Western world. Because the disease is highly metastatic and difficult to diagnosis until late stages, the 5-y survival rate is around 5%. The identification of molecular cancer drivers is critical for furthering our understanding of the disease and development of improved diagnostic tools and therapeutics. We have conducted a mutagenic screen using Sleeping Beauty ( SB ) in mice to identify new candidate cancer genes in pancreatic cancer. By combining SB with an oncogenic Kras allele, we observed highly metastatic pancreatic adenocarcinomas. Using two independent statistical methods to identify loci commonly mutated by SB in these tumors, we identified 681 loci that comprise 543 candidate cancer genes (CCGs); 75 of these CCGs, including Mll3 and Ptk2 , have known mutations in human pancreatic cancer. We identified point mutations in human pancreatic patient samples for another 11 CCGs, including Acvr2a and Map2k4 . Importantly, 10% of the CCGs are involved in chromatin remodeling, including Arid4b , Kdm6a , and Nsd3 , and all SB tumors have at least one mutated gene involved in this process; 20 CCGs, including Ctnnd1 , Fbxo11 , and Vgll4 , are also significantly associated with poor patient survival. SB mutagenesis provides a rich resource of mutations in potential cancer drivers for cross-comparative analyses with ongoing sequencing efforts in human pancreatic adenocarcinoma.